Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Ruggeri, 2002, Platelets in atherothrombosis., Nat Med, 8, 1227, 10.1038/nm1102-1227

Fuster, 2005, Atherothrombosis and high risk plaque. I. Evolving concepts., J Am Coll Cardiol, 46, 937, 10.1016/j.jacc.2005.03.074

Bhatt, 2006, International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis., JAMA, 295, 180, 10.1001/jama.295.2.180

2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation., N Engl J Med, 345, 494, 10.1056/NEJMoa010746

Chen, 2005, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial., Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X

Steinhubl, 2002, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial., JAMA, 288, 2411, 10.1001/jama.288.19.2411

Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation., N Engl J Med, 352, 1179, 10.1056/NEJMoa050522

Bhatt, 2004, Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial., Am Heart J, 148, 263, 10.1016/j.ahj.2004.03.028

1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction., N Engl J Med, 329, 673, 10.1056/NEJM199309023291001

Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study., Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4

Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel., Thromb Haemost, 84, 891, 10.1055/s-0037-1614133

Clarke, 2003, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin., Drug Metab Dispos, 31, 53, 10.1124/dmd.31.1.53

Kurihara, 2005, In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidative steps involved in the active metabolite formation [Abstract]., Drug Metab Rev, 37, 99

Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention., Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98

Gurbel, 2004, Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis., Platelets, 15, 95, 10.1080/09537100310001646950

Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction., Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03

Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity., Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83

Bates, 2005, Loading, pretreatment, and interindividual variability issues with clopidogrel dosing., Circulation, 111, 2557, 10.1161/CIRCULATIONAHA.105.536276

Kastrati, 2004, Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy., Circulation, 110, 1916, 10.1161/01.CIR.0000137972.74120.12

Montelascot, 2006, A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes., J Am Coll Cardiol, 48, 931, 10.1016/j.jacc.2006.04.090

Price, 2006, Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers., Am J Cardiol, 98, 681, 10.1016/j.amjcard.2006.03.054

Von Beckerath, 2005, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel., Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088

Niitsu, 2005, Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity., Semin Thromb Hemost, 31, 184, 10.1055/s-2005-869524

Sugidachi, 2000, The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties., Br J Pharmacol, 129, 1439, 10.1038/sj.bjp.0703237

Farid, 2007, Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry., Rapid Commun Mass Spectrom, 21, 169, 10.1002/rcm.2813

Rehmel, 2006, Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450., Drug Metab Dispos, 34, 600, 10.1124/dmd.105.007989

Paine, 2006, The human intestinal cytochrome p450 pie., Drug Metab Dispos, 34, 880, 10.1124/dmd.105.008672

Farid, 2007, The disposition of prasugrel, a novel thienopyridine, in humans., Drug Metab Dispos, 35, 1096, 10.1124/dmd.106.014522

Small, 2006, Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response., Am J Cardiol, 98, 200M

Jakubowski, 2005, Comparative antiplatelet effects of the active metabolites of CS-747 (prasugrel, LY640315) and clopidogrel [Abstract]., J Thromb Haemost, 3, 2299

Wiviott, 2006, Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38)., Am Heart J, 152, 627, 10.1016/j.ahj.2006.04.012

Jakubowski, 1985, Cumulative antiplatelet effect of low-dose enteric coated aspirin., Br J Haematol, 60, 635, 10.1111/j.1365-2141.1985.tb07467.x

Takahashi, 2006, Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS., J Am Soc Mass Spectrom, 17, 27S

Weerakkody, 2007, Clopidogrel poor responders: an objective definition based on Bayesian classification., Platelets, 18, 428, 10.1080/09537100701206790

Jernberg, 2006, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary heart disease., Eur Heart J, 27, 1166, 10.1093/eurheartj/ehi877

Payne, 2005, Superior inhibition of platelet aggregation following a loading dose of CS-747 (Prasugrel, LY640315) versus clopidogrel: correlation with the pharmacokinetics of active metabolite generation [Abstract]., J Thromb Haemost, 3, 0952

Sugidachi, 2005, Active metabolites of CS-747 (prasugrel, LY640315) and clopidogrel show similar in vitro P2Y12 receptor blockade but greater in vivo potency of CS-747 [Abstract]., J Thromb Haemost, 3, 1109

Kazui, 2005, Prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent, more efficiently generates active metabolite compared to clopidogrel [Abstract]., Drug Metab Rev, 37, 98

Lins, 1999, Necciari, et al. Pharmacokinetic profile of 14C-labeled clopidogrel., Semin Thromb Hemost, 25, 29

Angiolillo, 2007, Variability in individual responsiveness to clopidogrel., J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044

Brandt, 2007, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation., Am Heart J, 153, 66e9, 10.1016/j.ahj.2006.10.010

Hochholzer, 2006, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement., J Am Coll Cardiol, 48, 1742, 10.1016/j.jacc.2006.06.065

Jakubowski, 2007, Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects., J Cardiovasc Pharmacol, 49, 167, 10.1097/FJC.0b013e318031301b